VERASTEM ONCOLOGY ANNOUNCES UPDATED DATA FROM PARTNER GENFLEET THERAPEUTICS’ PHASE 1 STUDY IN CHINA OF GFH375 (VS-7375), AN ORAL KRAS G12D (ON/OFF) INHIBITOR

Reuters · 06/02 13:40

Please log in to view news